Marinus Pharmaceuticals Inc. (MRNS)

Name: Marinus Pharmaceuticals Inc. (MRNS) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Marinus Pharmaceuticals Inc. (MRNS)

Stock Card

$0.55

$0.00 (0.00%)

As on 11-Feb-2025 09:30EDT

Market cap

$30 Mln

Revenue (TTM)

$31 Mln

P/E Ratio

P/B Ratio

3.2

Div. Yield

0 %

Marinus Pharmaceuticals (MRNS) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 0.55 High: 0.55

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-29.9 %
ROCE

-- %
Industry P/E

37.32
EV/EBITDA

-34.5
Debt to Equity

-0.6
Book Value

$--
EPS

$-2.5
Face value

--
Shares outstanding

55,218,500

10 Years Aggregate

CFO

$-496.05 Mln

EBITDA

$-473.20 Mln

Net Profit

$-503.24 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Marinus Pharmaceuticals (MRNS)	2.8	2.4	59.2	-94.6	-64.0	-42.6	-35.4
BSE Sensex^*	-9.8	-2.2	2.8	-5.0	5.3	5.9	10.4
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 11-Feb-2025 | *As on 02-Sep-2026 | #As on 26-Oct-2023

Company	2024	2023	2022	2021	2020	2019	2018
Marinus Pharmaceuticals (MRNS)	-95.0	173.1	-66.5	-2.6	41.2	-24.7	-64.6
S&P Small-Cap 600	7.0	13.9	-17.4	25.3	9.6	20.9	-9.7
BSE Sensex	8.1	18.7	4.4	22.0	15.8	14.4	5.9

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About Marinus Pharmaceuticals (MRNS)

Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral... suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company's ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential. It is developing ganaxolone for treating genetic epilepsy disorders, such as PCDH19-related epilepsy, and tuberous sclerosis complex. Marinus Pharmaceuticals, Inc. has license agreement with Purdue Neuroscience Company and CyDex Pharmaceuticals, Inc.; and collaboration agreement with Orion Corporation and Tenacia Biotechnology (Shanghai) Co., Ltd. Marinus Pharmaceuticals, Inc. was incorporated in 2003 and is headquartered in Radnor, Pennsylvania. Read more

CEO, President & Chairman

Dr. Scott N. Braunstein M.D.
CEO, President & Chairman

Dr. Scott N. Braunstein M.D.
Headquarters

Radnor, PA
Website

https://marinuspharma.com

FAQs for Marinus Pharmaceuticals (MRNS)

What is the current share price of Marinus Pharmaceuticals Inc (MRNS) Today?

The share price of Marinus Pharmaceuticals Inc (MRNS) is $0.55 (NASDAQ) as of 11-Feb-2025 09:30 EDT. Marinus Pharmaceuticals Inc (MRNS) has given a return of -63.95% in the last 3 years.

What is the current PB & PE ratio of Marinus Pharmaceuticals Inc (MRNS)?

Since, TTM earnings of Marinus Pharmaceuticals Inc (MRNS) is negative, P/E ratio is not available.
The P/B ratio of Marinus Pharmaceuticals Inc (MRNS) is 3.17 times as on 11-Feb-2025, a 59 discount to its peers’ median range of 7.75 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2023	-4.36	36.76
2022	-9.03	1.54
2021	-4.29	8.16
2020	-5.83	2.83
2019	-0.87	0.53

What is the 52 Week High and Low of Marinus Pharmaceuticals Inc (MRNS)?

The 52-week high and low of Marinus Pharmaceuticals Inc (MRNS) are Rs -- and Rs -- as of 02-Sep-2026.

What is the market cap of Marinus Pharmaceuticals Inc (MRNS)?

Marinus Pharmaceuticals Inc (MRNS) has a market capitalisation of $ 30 Mln as on 11-Feb-2025. As per SEBI classification, it is a Small Cap company.

Should I invest in Marinus Pharmaceuticals Inc (MRNS)?

Before investing in Marinus Pharmaceuticals Inc (MRNS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.